GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B1328 Terbutaline SulfateSummary: Selective β2-adrenergic receptor agonist
- B1349 Tetrahydrozoline HClSummary: Adrenergic receptor agonist
- B1329 Tolazoline HClSummary: non-selective competitive α-adrenergic receptor antagonist
- B2259 VUF 10166Target: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist
- B2260 WAY-100635 maleate saltSummary: 5-HT1A receptor antagonist
- B1339 Metoprolol TartrateSummary: β1-adrenergic blocking agent
- B1336 Isoprenaline HClSummary: β-adrenergic receptor agonist
- B1351 Xylazine HClSummary: α2 Adrenoceptor agonist
- B1367 SotalolSummary: Adrenergic receptor antagonist
- B1357 Dexmedetomidine HClSummary: Highly selective and potent alpha-2 adrenoceptor agonist